Recently PharmAust has made reference to itself as :
A Mid-stage biotechnology company targeting human neurodegenerative diseases.
While most focus on other threads is on MND/ALS, the company is now exploring the application of MPL in other other neurodegenerative diseases.
Demonstrating potential efficacy of MPL in other indications will significantly add to the value of PharmAust.
This thread is designed to capture information pertinent to MPL and these additional neurodegenerative conditions.
Some recent comments from presentations & the investor hub :
Neurodegenerative Indications other than MND/ALS
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.015(7.32%) |
Mkt cap ! $87.1M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 21.0¢ | $134.7K | 629.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24563 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 64222 | 3 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
21.5¢ |
Change
0.015 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 21.0¢ | 22.0¢ | 21.0¢ | 340156 | ||
| Last updated 15.57pm 07/06/2024 ? | |||||
| PAA (ASX) Chart |